Gimeracil

• Description:

  Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) [1][2].

• Product Name Alternative:

  Gimestat

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Dihydropyrimidine Dehydrogenase (DPD) ; DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/gimeracil.html

• Concentration:

  10mM

• Purity:

  99.72

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C(O)C(Cl)=CN1

• Molecular Formula:

  C5H4ClNO2

• Molecular Weight:

  145.54

• Precautions:

  H302

• References & Citations:

  [1]Masaru Takagi, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010 Aug;96 (2) :259-66.|[2]Koh-Ichi Sakata, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011 Sep;102 (9) :1712-6.|[3]Masakazu Fukushima, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010 Nov;24 (5) :1307-13.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [103766-25-2]